Relevance of extracellular and intracellular interactions of camptothecins as determinants of antitumor activity

被引:38
作者
Beretta, Giovanni Luca [1 ]
Zunino, Franco [1 ]
机构
[1] IRCCS Fdn, Ist Nazl Tumori, Dept Expt Oncol & Labs, I-20133 Milan, Italy
关键词
camptothecin; antitumor pharmacology; DNA damage; transporters; human serum albumin; DNA topoisomerase;
D O I
10.1016/j.bcp.2007.04.027
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Camptothecins are potent antitumor agents that stabilize the covalent binding of topoi-somerase I to DNA forming a reversible ternary complex which, following collision with the replication forks, converts the single-strand breaks into lethal double-strand breaks. This cytotoxic mechanism has been originally acribed to the closed lactone form, becuase opening of the lactone ring resulted in loss of antitumor activity. Since the lipophilic lactone favours passive diffusion into the cancer cells, the stabilityof the closed form is expected to be predictive for activity. Thus, the in vivo pharmacological behavior of camptothecins, which is dependent on the pH-dependent dynamics, is likely a critical determinant of their antitumor efficacy and therapeutic index. The physicochemical properties could influence a number of cellular and in vivo interactions, including stability of the ternary DNA-enzymedrug complex, binding to serum proteins, recognition by transport systems. These interactions are also implicated in the processes responsible of toxic side effects and drug resistance which are major limitations of the efficacy of camptothecin -based therapy. A number of strategies have been developed to overcome the limitations associated with the peculiar in vivo reactivity and the reversibility of drug-target interaction. Modifications with hydrophilic or lipophilic substituents at specific positions may have a variable (and somewhat opposite) influence on interaction with the intracellular target and plasma proteins and on recognition by membrane transporters. Here, we highlight the interactions of camptothecins which could be exploited to optimize therapeutic efficacy. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:1437 / 1444
页数:8
相关论文
共 73 条
[1]   PHASE-I AND PHARMACOLOGICAL STUDIES OF THE CAMPTOTHECIN ANALOG IRINOTECAN ADMINISTERED EVERY 3 WEEKS IN CANCER-PATIENTS [J].
ABIGERGES, D ;
CHABOT, GG ;
ARMAND, JP ;
HERAIT, P ;
GOUYETTE, A ;
GANDIA, D .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (01) :210-221
[2]   Camptothecin analogs with enhanced activity against human breast cancer cells. II. Impact of the tumor pH gradient [J].
Adams, DJ ;
Wahl, ML ;
Flowers, JL ;
Sen, B ;
Colvin, M ;
Dewhirst, MW ;
Manikumar, G ;
Wani, MC .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 57 (02) :145-154
[3]  
Allen JD, 2002, CANCER RES, V62, P2294
[4]  
Allen JD, 1999, CANCER RES, V59, P4237
[5]   P-glycoprotein: from genomics to mechanism [J].
Ambudkar, SV ;
Kimchi-Sarfaty, C ;
Sauna, ZE ;
Gottesman, MM .
ONCOGENE, 2003, 22 (47) :7468-7485
[6]   Biochemical, cellular, and pharmacological aspects of the multidrug transporter [J].
Ambudkar, SV ;
Dey, S ;
Hrycyna, CA ;
Ramachandra, M ;
Pastan, I ;
Gottesman, MM .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1999, 39 :361-398
[7]   ABCG2 mediates differential resistance to SN-38 (7-ethyl-10-hydroxycamptothecin) and homocamptothecins [J].
Bates, SE ;
Medina-Pérez, WY ;
Kohlhagen, G ;
Antony, S ;
Nadjem, T ;
Robey, RW ;
Pommier, Y .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 310 (02) :836-842
[8]   Biological properties of IDN5174, a new synthetic camptothecin with the open lactone ring [J].
Beretta, Giovanni L. ;
Petrangolini, Giovanna ;
De Cesare, Michelandrea ;
Pratesi, Graziella ;
Perego, Paola ;
Tinelli, Stella ;
Tortoreto, Monica ;
Zucchetti, Massimo ;
Fraponi, Roberta ;
Bello, Ezia ;
Manzotti, Carla ;
Fontana, Gabriele ;
Bombardelli, Ezio ;
Battaglia, Arturo ;
Samori, Cristian ;
Zunino, Franco .
CANCER RESEARCH, 2006, 66 (22) :10976-10982
[9]   The highly lipophilic DNA topoisomerase I inhibitor DB-67 displays elevated lactone levels in human blood and potent anticancer activity [J].
Bom, D ;
Curran, DP ;
Zhang, J ;
Zimmer, SG ;
Bevins, R ;
Kruszewski, S ;
Howe, JN ;
Bingcang, A ;
Latus, LJ ;
Burke, TG .
JOURNAL OF CONTROLLED RELEASE, 2001, 74 (1-3) :325-333
[10]   The novel silatecan 7-tert-butyldimethylsilyl-10-hydroxycamptothecin displays high lipophilicity, improved human blood stability, and potent anticancer activity [J].
Bom, D ;
Curran, DP ;
Kruszewski, S ;
Zimmer, SG ;
Strode, JT ;
Kohlhagen, G ;
Du, W ;
Chavan, AJ ;
Fraley, KA ;
Bingcang, AL ;
Latus, LJ ;
Pommier, Y ;
Burke, TG .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (21) :3970-3980